Abstract
Alpha-1 antitrypsin deficiency (AATD) is an important risk factor for development of chronic obstructive pulmonary disease (COPD). Patients with AATD classically develop a different pattern of lung disease from those with usual COPD, decline faster and exhibit a range of differences in pathogenesis, all of which may be relevant to phenotype and/or impact of exacerbations. There are a number of definitions of exacerbation, with the main features being worsening of symptoms over at least 2 days, which may be associated with a change in treatment. In this article we review the literature surrounding exacerbations in AATD, focusing, in particular, on ways in which they may differ from such events in usual COPD, and the potential impact on clinical management.
| Original language | English |
|---|---|
| Pages (from-to) | 162-176 |
| Number of pages | 15 |
| Journal | Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation |
| Volume | 8 |
| Issue number | 1 |
| Early online date | 19 Nov 2020 |
| DOIs | |
| Publication status | Published - Jan 2021 |
Bibliographical note
JCOPDF © 2021.Keywords
- COPD
- emphysema
- chronic obstructive pulmonary disease
- alpha-1 antitrypsin deficiency
- exacerbation
- neutrophil
Fingerprint
Dive into the research topics of 'Exacerbations of Lung Disease in Alpha-1 Antitrypsin Deficiency'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver